HTV-1 infects the central nervous system (CNS) and may cause AIDS dementia complex (ADC) and other neurologic complications. The cerebrospinal fluid (CSF) virus load is usually 0,5 -1 log lower than in blood, but in some patients the CSF quantitative HIV-1 RNA values exceed the paired blood samples. CSF neopterin concentrations are increased in all stages of HIV-1 infection, with the highest concentrations in AIDS patients and patients with CNS opportunistic infections. CD4 cell count and quantitative HIV RNA PCR tests in peripheral blood are used in clinical practice to monitor the HIV-1 infection and the anti-retroviral treatment effect. In most patients the anti-retroviral treatment response is similar in the cerebrospinal fluid (CSF) compare to the peripheral blood and the CSF viral load and neopterin concentrations are markedly reduced following treatment. ADC has become a rare complication. In spite of virological effective treatment many patients have a low grade intrathecal immunoactivation, measured as CSF neopterin concentrations above the 95% confidence interval found in IIIV-1 negative controls, after such a long time as after 2 years of anti-retroviral treatment. The risk of long term intrathecal immunoactivation and which anti-retroviral combination treatment has the best effect on CSF parameters is not known. CSF neopterin concentrations are at present not used in clinical practice but may add valuable information.
Introduction
HIV-1 spreads to the central nervous system (CNS) during or in association with the primary infection (1, 2) , and is detected in cerebrospinal fluid (CSF) (1) and the brain (3), establishing a low-grade chronic process within the central nervous system (4) . Despite the infectious CNS activity, the vast majority of HIVinfected patients have no neurological symptoms for several years. At later stages of disease, an encephalopathy also known as AIDS dementia complex (ADC) may develop in around 20 % of untreated AIDS patients (5, 6) . This is a neurological syndrome characterised by cognitive, motor and behavioural dysfunction (7) . It has been debated since almost 20 years whether asymptomatic HIV-1 infected individuals are doing worse in neuropsychiatrie tests than matched controls.
The ADC diagnosis is clinical when other causes of dementia such as opportunistic infections or tumours have been ruled out. There are no established diagnostic laboratory tests for ADC or prognostic CSF markers for identifying HIV individuals who are at risk for developing ADC. The CSF viral load has little prognostic sensitivity. Although unspecific, surrogate markers of intrathecal immune activation such as neopterin and beta-2-microglobulin have been suggested to be more sensitive. Before quantitative HIV RNA PCR tests were in clinical practice (i.e.beforel996), the CD4 cell count was the only routine surrogate blood marker used for estimation of the level and the progress of the HIV infection. CD4 cell count is an excellent test for determining how far the immune function has deteriorated but is less useful to estimate the speed of disease progression. There was a need for better markers of the infection dynamics and both neopterin and beta-2-microbglobulin concentrations were shown to be of The closest compartment to measure CNS infection is the CSF. Under healthy conditions, no inflammatory activity is seen in CSF, and the cell count is low. Neopterin is detectable in low concentrations in CSF under healthy conditions. In 24 healthy controls CSF neopterin concentrations ranged between 3.2 and 5.5 nmol/l (mean 4.2 nmol/1) with the RIA method (Henning Berlin) (9) . The normal levels of CSF neopterin increase with age ( fig 1) . In 47 individuals regarded as healthy (aged 18-76 years) where spinal fluid analysis was done because of headache, or vertigo but infection and other diseases were not found, and with normal CSF albumin and cell count, the neopterin concentrations were in mean 4.0 nmol/1 with 95% confidence interval of 3.7 -4.3 nmol/1 (RIA method Henningtest Neopterin, BRAHMS, Berlin Germany) ( Fig. 1 ) tic CNS infections, but increased levels are also a frequent finding in asymptomatic HIV-1-infected individuals (9, 10, 11, 12) . The CNS HIV-1 infection triggers an intrathecal immune response also in patients without neurological symptoms (4) , and the intrathecal immunoactivation seems to correspond to the CSF viral load (13) . Before antiretroviral therapy was available normal CSF neopterin concentrations were an uncommon finding during HIV-1 infection. In the first consecutive 100 HIV patients included in our CSF study, representing an unselected clinical material before introduction of antiretroviral treatment 1985-1989, only 7 patients had CSF neopterin concentrations below 6 nmol/L and none had below 5 nmol/L. In a later clinical material (14) 63 asymptomatic HIV-1 infected patients had CSF neopterin concentration of in mean 18.6 nmol/1 (around 3 times higher than the controls). The CSF neopterin concentrations were higher than in the paired serum samples ( 14.2 nmol/1 ) (not significantly p=0.2) (Tab. 1). AIDS patients of whom none had CNS opportunistic infections had in mean 4.5 times higher CSF neopterin levels than the healthy controls. In patients with opportunistic CNS 
CSF Neopterin in HIV infection
High CSF neopterin concentrations are found in HIV-1-infected patients with dementia or opportunisinfections, AIDS patients with CMV encephalitis have higher CSF neopterin concentrations than patents with toxoplasmosis encephalitis or progressive multifocal encephalopathy (15) .
Further data indicate a pronounced CSF inflammatory activity in many patients during HIV infection. A higher baseline neopterin levels in CSF than in plasma was found in 57 % of the patients while 22% had higher HIV-1 RNA levels in CSF than in plasma (16) . Since over half of the patients have higher levels of neopterin in CSF than in serum, intrathecal production is assumed. This confirms previous estimations that only a fraction of the CSF neopterin originate from outside the CNS (17) . How is it possible that HIV-1 infection in many patients gives a more prominent inflammatory activity measured as neopterin concentration in CSF, a fluid with 1000 times less numbers of mononuclear cells than in peripheral blood? Probably, other cells must be the source of the neopterin such as the monocytic derived microglia cells.
CSF neopterin and anti-retroviral combination treatment
Modern antiretroviral combination treatment effectively reduces HIV-RNA in blood, CSF (18, 19) , and also the intrathecal immunoactivation (20) . An example of the treatment effect is shown in an AIDS patient in (Tab. 2), and the positive effect persisted for a very long follow up time. However, the CSF neopterin concentration did not reach the normal reference values case. Before 1996, when patients were treated with only one or two anti-retroviral drugs, it was observed that this inadequate treatment was more efficient in CSF than in blood (21) . For example, single zidovudine treatment lowered the viral CSF load for longer time than in blood and reduced the incidence of ADC (5) . It might thus be easier to lower the viral load to undetectable levels in CSF than in blood.
After 1996 most anti-retroviral combinations have been shown to reduce the CSF viral load to levels below routine detection. However, only 55 % of effectively anti-retroviral treated patients had CSF neopterin concentrations within normal levels after two years (20) . This indicates an ongoing immunoactivation within the brain despite effective antiretroviral treatment, albeit, on a much lower level than without treatment. Several possible explanations for persisting intrathecal immune stimulation in HIV-infection may be suggested. The lingering abnormal CSF neopterin levels might reflect a remaining low viral replication which is unable to quantify with the current test methods. If that were true, CSF neopterin concentrations is an alternative or maybe even a better approach to evaluate the effect of combination antiretroviral therapy on the CNS HIV-1 infection in neuro-asymptomatic patients than viral load. On the other hand, the intrathe- CSF neopterin and markers of neuronal destruction
Markers of various CNS cell destruction or cell turn-over are possible to measure in CSF. In AIDS patients the CSF concentrations of the light subunit of the neurofilament protein (NFL, a marker of neurons, mainly axons) are often elevated indicating neuronal destruction. In contrast to the CSF viral load, the CSF neopterin correlated to the CSF NFL concentrations ( 23) . This finding support the theory that immune activation rather than the HIV viral load is associated with HIV CNS disease. CSF neopterin might thus be a better marker of the risk for developing AIDS dementia than quantitative HIV assays.
Conclusions
As yet, neopterin concentrations have not been established as a routine test for monitoring the natural course of HIV infection, nor to monitor treatment effects. Most clinicians are satisfied with CD4 cell count and quantitative HIV RNA tests. Since effective treatment (measured as < 50 copies/ml in blood) also has been shown to be effective within the CSF compartment, there has been little need for additional CSF tests. The central nervous system has luckily not been a compartment difficult to treat, and ADC is rarely developing nowadays. However, there are limited numbers of methods to monitor a CNS infection compared with blood tests. Tests such as C reactive protein, sedimentation rate and CD4 cell count are not possible or meaningful to perform in the CSF. Mononuclear cell count is easily done, but the immune deficiency in AIDS patients probably impairs the recruitment of cells at least in patients without opportunistic infections. Therefore a marker of immunoactivation may add valuable information.
The HIV epidemic in developing countries has seen various phases in respect of treatment options; before 1987 there was no anti-retroviral drugs available; between 1987 and 1996 there was an increasing number of drugs but no effective combination available; and after 1996 there has been effective anti-retroviral treatment combinations and we have seen dramatic positive clinical effects. The next phase among other things will focus on long term side effects of antiretroviral drugs and effect of immunoactivation caused by residual low HIV viral load. It is not known how the brain reacts to a low grade immunostimulation going on for decades. Further studies are needed to evaluate the risk of long term intrathecal immunoactivation and which combination treatment have best effect not only on the viral load but also on the inflammatory response. Although unspecific, neopterin concentrations might be a useful parameter in this respect.
